TG Therapeutics TGTX Accrued Compensation
Accrued Compensation at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredCompensationLiabilityCurrent.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's accrued compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's accrued compensation?
- TG Therapeutics (TGTX) reported accrued compensation of $18.66M in Q1 2026.
- How has TG Therapeutics's accrued compensation changed year-over-year?
- TG Therapeutics's accrued compensation increased by 263.3% year-over-year, from $5.14M to $18.66M.
- What is the long-term trend for TG Therapeutics's accrued compensation?
- Over 5 years (2020 to 2025), TG Therapeutics's accrued compensation has grown at a 20.9% compound annual growth rate (CAGR), from $8.46M to $21.85M.
- What does accrued compensation mean?
- Wages and bonuses earned by employees but not yet paid out.
- How do you interpret accrued compensation?
- Increases often correlate with headcount growth or the accrual of performance-based bonuses, while decreases may signal the timing of bonus payouts.
- How does accrued compensation compare across companies?
- Accrued compensation is a standard liability for all companies, with levels typically proportional to the size and compensation structure of the workforce.